Otsuka Pharmaceutical Development & Commercialization

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Otsuka Pharmaceutical Development & Commercialization sits in the top decile of US sponsors by registered trial count (#145 of 15,742 sponsors by registered trial count).

221 total trials 8 currently recruiting 186 completed top decile by trial count

Otsuka Pharmaceutical Development & Commercialization: 221 sponsored US clinical trials, 8 recruiting.

Otsuka Pharmaceutical Development & Commercialization sponsors 221 registered US clinical trials on ClinicalTrials.gov, 8 of them currently recruiting, and 186 completed. 119 of these trials are in Phase 3-4 (later-stage) and 97 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Schizophrenia, with 12 trials.

Top-decile sponsor footprint

Otsuka Pharmaceutical Development & Commercialization ranks in the top decile of sponsors by registered trial count (#145 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 63/100

186 of 208 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

221 total, page 5 of 5

COMPLETED Phase 3

CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission

NCT00092508
COMPLETED Phase 4

Study of Aripiprazole in Subjects With Alcoholism

NCT00082199
COMPLETED Phase 3

Aripiprazole Oral Acceptability Trial

NCT00101569
COMPLETED Phase 3

Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder

NCT00095524
COMPLETED Phase 3

Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode

NCT00080314
COMPLETED Phase 3

Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia

NCT00095719
COMPLETED Phase 4

Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia

NCT00080327
COMPLETED Phase 3

EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan

NCT00071331
COMPLETED Phase 4

Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease

NCT00095810
COMPLETED Phase 3

FACTS I: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis

NCT00064441
COMPLETED Phase 3

FACTS II: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis

NCT00064454
COMPLETED Phase 3

"SALT Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia

NCT00072683
COMPLETED Phase 2

Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy Study on the Effects of Tolvaptan on Left Ventricular Dilatation in Congestive Heart Failure Patients

NCT00043758
COMPLETED Phase 3

Broad Effectiveness: Study With Aripiprazole

NCT00036361
COMPLETED Phase 3

Study of Aripiprazole in the Treatment of Patients With Acute Symptoms of Bipolar Disorder

NCT00046384
COMPLETED Phase 2

Study to Compare the Effects of Two Dosages of Tolvaptan in Congestive Heart Failure Patients

NCT00043771
COMPLETED Phase 2

Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders

NCT00036127
COMPLETED Phase 3

Study of Aripiprazole in the Treatment of Patients With Acute Symptoms in Bipolar Disorder

NCT00036101
COMPLETED Phase 3

Study of Aripiprazole in Patients With a History of Bipolar Disorder

NCT00036348
COMPLETED Phase 3

Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type

NCT00036114
COMPLETED Phase 3

Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type

NCT00041678
← Previous Page 5 of 5

Phase Distribution

PhaseTrial count
Phase 1 52
Phase 2 45
Phase 3 109
Phase 4 10

Therapeutic Areas

Schizophrenia 12
Alzheimers Disease 4
Alzheimer's Type 3
Bipolar I Disorder 3
Mental Disorder 3
Nervous System Diseases 3
Bipolar Disorder 3
Major Depressive Disorder 3
Agitation Associated With 2
Acute Schizophrenia 2

What is open in the Otsuka Pharmaceutical Development & Commercialization pipeline

8 recruiting of 221 indexed (4% open); 186 completed (84%).

Phase mix: 119 late (III/IV) vs 97 early (I/II) (balanced across stages).

Top condition: Schizophrenia (12 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Otsuka Pharmaceutical Development & Commercialization: open-pipeline peers nationwide

Peers matched on 221 registered trials and 4% open enrollment, not the therapeutic-area sidebar.

Otsuka Pharmaceutical Development & Commercialization sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 050100150200250 0%5%10%15%20%25% Total trials Recruiting share Otsuka Pharmaceutical Development & CommercializationNational Eye Institute (NEI)Florida State UniversityPenn State UniversityUniversity of LouisvilleTeva Branded Pharmaceutical Products R&DBausch Health AmericasHarvard Pilgrim Health CareSumitomo Pharma America
Otsuka Pharmaceutical Development & Commercialization sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Otsuka Pharmaceutical Development & Commercialization sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 221 trials (± recruiting share)

Sponsors near 4% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Otsuka Pharmaceutical Development & Commercialization page

221 registered trials is a research-attention snapshot, not an endorsement of Otsuka Pharmaceutical Development & Commercialization or any single study.

  • 8 of Otsuka Pharmaceutical Development & Commercialization's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Schizophrenia is the condition Otsuka Pharmaceutical Development & Commercialization studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Schizophrenia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Otsuka Pharmaceutical Development & Commercialization pipeline card: 221 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.